Economic assessment of platelet glycoprotein IIb/IIIa inhibition for prevention of ischemic complications of high-risk coronary angioplasty

Circulation

Volumn 94, Issue 4, 1996, Pages 629-635

  Mark, Daniel B ^a,c   Talley, J David ^d   Topol, Eric J ^h   Bowman, Lee ^j   Lam, Lai Choi ^a   Anderson, Keaven M ⁱ   Jollis, James G ^a   Cleman, Michael W ^e   Lee, Kerry L ^b,c   Aversano, Thomas ^f   Untereker, William J ^g   Davidson Ray, Linda ^a   Califf, Robert M ^b  

^a Econ and Qual of Life Res Group   (United States)

^b Division of Cardiology   (United States)

^c DUKE UNIVERSITY MEDICAL CENTER   (United States)

^d University of Louisville School of Medicine   (United States)

^e YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^f JOHNS HOPKINS HOSPITAL   (United States)

^g Department of Anesthesiology   (United States)

^h LERNER RESEARCH INSTITUTE   (United States)

ⁱ CENTOCOR INC   (United States)

^j ELI LILLY AND COMPANY   (United States)

more..

Author keywords

angioplasty; cost benefit analysis; glycoproteins; trials

Indexed keywords

ABCIXIMAB; ACETYLSALICYLIC ACID; FIBRINOGEN RECEPTOR; FIBRINOGEN RECEPTOR ANTAGONIST; HEPARIN; PLACEBO;

ADULT; AGED; ARTICLE; BLEEDING; BOLUS INJECTION; CLINICAL PROTOCOL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COST BENEFIT ANALYSIS; COST CONTROL; DOUBLE BLIND PROCEDURE; DRUG COST; FEMALE; HEART MUSCLE ISCHEMIA; HEART MUSCLE REVASCULARIZATION; HIGH RISK PATIENT; HOSPITAL COST; HOSPITALIZATION; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; MAJOR CLINICAL STUDY; MALE; MEDICAL FEE; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RESTENOSIS; THROMBOCYTE AGGREGATION INHIBITION; TRANSLUMINAL CORONARY ANGIOPLASTY; TREATMENT OUTCOME;

EID: 9544243719     PISSN: 00097322     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.CIR.94.4.629     Document Type: Article

References (15)

1. Lincoff AM, Topol EJ. Abrupt vessel closure. In: Topol EJ, ed. Textbook of Interventional Cardiology. 2nd ed. Philadelphia, Pa: WB Saunders Co; 1994:207-230.
2. The EPIC Investigators. Use of a monoclonal antibody directed against the platelet glycoprotein IIb/IIIa receptor in high-risk coronary angioplasty. N Engl J Med. 1994;330:956-961.
3. Topol EJ, Califf RM, Weisman HF, Ellis SG, Tcheng JE, Worley S, Ivanhoe R, George BS, Fintel D, Weston M, Sigmon K, Anderson KM, Lee KL, Willerson JT, on behalf of the EPIC Investigators. Randomised trial of coronary intervention with antibody against platelet IIb/IIIa integrin for reduction of clinical restenosis: results at six months. Lancet. 1994;343:881-886.
4. Hillegass WB, Ohman EM, Califf RM. Restenosis: the clinical issues. In: Textbook of Interventional Cardiology. 2nd ed. Philadelphia, Pa: WB Saunders Co; 1994:415-435.
5. Lincoff AM, Popma JJ, Ellis SG, Hacker JA, Topol EJ. Abrupt vessel closure complicating coronary angioplasty: clinical, angiographic and therapeutic profile. J Am Coll Cardiol. 1992;19:926-935.
6. Tenaglia AN, Fortin DF, Frid DJ, Gardner LH, Nelson CL, Tcheng JE, Stack RS, Califf RM. Long-term outcome following successful reopening of abrupt closure after coronary angioplasty. Am J Cardiol. 1993;72:21-25.
7. Fortin DF, Tcheng JE, Hillegass WB, Phillips HR III. Clinical management of restenosis. In: Roubin GS, Califf RM, O'Neill WW, Phillips HR III, Stack RS, eds. Interventional Cardiovascular Medicine: Principles and Practice. New York, NY: Churchill-Livingstone; 1994:555-573.
8. Reeder GS, Krishan I, Nobrega FT, Naessens J, Kelly M, Christianson JB, McAffee MK. Is percutaneous coronary angioplasty less expensive than bypass surgery? N Engl J Med. 1984;311:1157-1162.
9. Ryan TJ, Faxon DP, Gunnar RM, Kennedy JW, King SB III, Loop FD, Peterson KL, Reeves TJ, Williams DO, Winters WL Jr. Guidelines for percutaneous transluminal coronary angioplasty: a report of the American College of Cardiology/American Heart Association Task Force on Assessment of Diagnostic and Therapeutic Cardiovascular Procedures (Subcommittee on Percutaneous Transluminal Coronary Angioplasty). Circulation. 1988;78:486-502.
10. Aguirre F, Topol EJ, Ferguson JJ, Anderson K, Blankenship JC, Heuser RR, Sigmon K, Taylor M, Gottlieb R, Hanovich G, Rosenberg M, Donohue TJ, Weisman HF, Califf RM. Bleeding complications with the chimeric antibody to platelet glycoprotein IIb/IIIa integrin in patients undergoing percutaneous coronary intervention. Circulation. 1995;91:2882-2890.
11. Mark DB. Medical economics and health policy issues for interventional cardiology. In: Topol EJ, ed. Textbook of Interventional Cardiology. 2nd ed. Philadelphia, Pa: WB Saunders Co; 1993:1323-1353.
12. Hlatky MA, Lipscomb J, Nelson C, Califf RM, Pryor DB, Wallace AG, Mark DB. Resource use and cost of initial coronary revascularization: coronary angioplasty versus coronary bypass surgery. Circulation. 1990;82(suppl IV):IV-208-IV-213.
13. Finkler SA. The distinction between costs and charges. Ann Intern Med. 1982;96:102-109.
14. Dudley RA, Harrell FE Jr, Smith LR, Mark DB, Califf RM, Pryor DB, Glower D, Lipscomb J, HIatky MA. Comparison of analytic models for estimating the effect of clinical factors on the cost of coronary artery bypass graft surgery. J Clin Epidemiol. 1993;46:261-271.
15. Shadoff N, Califf RM, for the EPIC Study Group. Impact of clinical site on ischemic events and bleeding complications: results from the EPIC trial. J Am Coll Cardiol. 1994;23:404A. Abstract.